(RTTNews) - Seelos Therapeutics, Inc. (SEEL) has received an acknowledgement letter of a Clinical Trial Notification from the Australian Government Department of Health Therapeutic Goods Administration for a pilot study of SLS-005 for the treatment of patients with Alzheimer's disease. Also, Seelos received authorization to conduct a separate open-label basket study in Australia to evaluate the effectiveness of SLS-005 in participants with selected neurodegenerative diseases including Huntington's disease.
SLS-005 is a low molecular weight disaccharide that crosses the blood brain barrier and is thought to stabilize proteins and activate autophagy through the activation of Transcription Factor EB, a key factor in lysosomal and autophagy gene expression.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
